The Risk of Cancer Progression in Women With Gynecological Malignancies and Thrombophilic Polymorphisms: A Pilot Case-Control Study

Abstract

Cancer produces a hypercoagulable state, which might lead to thrombosis, and on contrary, unprovoked venous thromboembolism might be the manifestation of an occult cancer. In this pilot case-control study, we assessed the risk of gynecological malignant diseases related to the presence of the factor V Leiden and prothrombin G20210A polymorphisms. Fifty-two women underwent an operation for gynecological malignancy and were enrolled in the study. Women who underwent an operation for gynecological nonmalignant disease in the same days of cases were considered as controls. The presence of factor V Leiden and prothrombin G20210A was assessed in case and control groups. In all, 7 out of 52 cases were carriers of the 2 polymorphisms compared with 20 out of 198 controls (odds ratio = 1.3; 95% confidence interval, 0.6-3.0). The results were also similar when the risk was considered separately for the site of cancer. As for advanced and metastatic malignancies, the odds ratios were 2.3 (95% confidence interval, 0.9-6.0) and 3.3 (95% confidence interval, 1.0-11), respectively, compared to noncancer patients. When these 2 groups were compared to nonadvanced cancer group, the odds ratios for carriers of polymorphisms were 2.7 (95%confidence interval, 0.7-11.0) and 3.9 (95%confidence interval, 0.8-18.6) for advanced cancer and metastatic malignancies, respectively. Women with factor V Leiden or prothrombin G20210A polymorphisms who developed gynecological malignancy might present with a higher stage of cancer at the time of surgery. Larger case-control studies in similar cohort of patients are needed to confirm these findings.

Keywords

factor V Leiden G20210A prothrombin variant cancer

References

Rickles FR , Levine MN Epidemiology of thrombosis in cancer. Acta Haematol. 2001;106:6-12.

Thodiyil PA , Kakkar AK Variation in relative risk of venous thromboembolism in different cancers . Thromb Haemost. 2002;87:1076-1077.

López JA , Kearon C. , Lee AY Deep venous thrombosis. Hematology Am Soc Hematol Educ Program. 2004;1:439-456.

Falanga A. , Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol. 2005;16:696-701.

Prandoni P. , Falanga A. , Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6:401-410.

Aderka D. , Brown A. , Zelikovski A. , Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer. 1986;57:1846-1849.

Monreal M. , Lafoz E. , Casals A. , et al. Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer. 1991;67:541-545.

Nordstrom M. , Lindblad B. , Anderson H. , Bergqvist D. , Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ. 1994;308: 891-894.

Sorensen HT , Mellemkjaer L. , Olsen JH , Baron JA Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850.

10.

Morgan MA , Iyengar TD , Napiorkowski BE , Rubin SC , Mikuta JJ The clinical course of deep vein thrombosis in patients with gynecologic cancer . Gynecol Oncol. 2002;84:67-71.

11.

Taliani MR , Agnelli G. , Prandoni P. , et al. Warfarin Optimal Duration Italian Trial (WODIT) Investigators. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost. 2003;1:1730-1733.

12.

Lee AY Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms. Hematology Am Soc Hematol Educ Program. 2006; 1:438-443.

13.

Fennerty A. Venous thromboembolic disease and cancer. Postgrad Med J. 2006;82:642-648.

14.

Falanga A. Thrombophilia in cancer. Semin Thromb Hemost. 2005;31:104-110.

15.

Miller GJ , Bauer KA , Howarth DJ , Cooper JA , Humphries SE , Rosenberg RD Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost. 2004;2:2107-2114.

16.

Mandalà M. , Curigliano G. , Bucciarelli P. , et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol. 2004; 15:590-593.

17.

Kennedy M. , Andreescu AC , Greenblatt MS , et al. Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. Br J Haematol. 2005 ;128:386-388.

18.

Blom JW , Doggen CJ , Osanto S. , Rosendaal FR Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-722.

19.

Eroglu A. , Ulu A. , Cam R. , Kurtman C. , Akar N. Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. J Thromb Thrombolysis. 2007;23:31-34.

20.

Paspatis GA , Sfyridaki A. , Papanikolaou N. , et al. Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiol Haemost Thromb. 2002;32:2-7.

21.

Pihusch R. , Danzl G. , Scholz M. , et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer. 2002; 94:3120-3126.

22.

Battistelli S. , Stefanoni M. , Genovese A. , Vittoria A. , Cappelli R. , Roviello F. Prevalence of factor V Leiden and prothrombin G20210A in patients with gastric cancer. World J Gastroenterol . 2006;12:4179-4180.

23.

Simioni P. , Prandoni P. , Lensing AW , et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood. 2000;96:3329-3333.

24.

Vlodavsky I. , Ilan N. , Nadir Y. , et al. Heparanase, heparin and the coagulation system in cancer progression. Thromb Res. 2007;120(suppl 2):112S-120S.